# Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

> **NCT02887248** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 3 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer
- Transitional Cell Carcinoma

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02887248
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-12
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-05-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Enrollment issues
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02887248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02887248, "Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02887248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*